What prices were involved in Helen Collins’ Enliven (ELVN) option exercise and share sale?

Helen Louise Collins exercised stock options at an exercise price of $2.48 per share and sold 40,000 shares of Enliven Therapeutics common stock at a weighted average sale price of $35.1006, with individual trades ranging from $35.00 to $35.25.

Enliven (NASDAQ: ELVN) CMO exercises options and sells 40K shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Enliven Therapeutics’ chief medical officer Helen Louise Collins exercised stock options and sold shares in a planned transaction. She exercised options for 40,000 shares of common stock at an exercise price of $2.48 per share and sold 40,000 shares at a weighted average price of $35.1006 per share. The filing states these trades were made under a Rule 10b5-1 trading plan adopted on October 19, 2025, indicating they were pre-scheduled. Following the transactions, Collins directly owns 25,000 shares of common stock and continues to hold 136,268 equity awards, including fully vested options and RSUs.

Insider Trade Summary 10b5-1

Net Seller: 40,000 shares ($1,404,024)

Net Sell 3 txns

Insider Collins Helen Louise

Role CHIEF MEDICAL OFFICER

Sold 40,000 shs ($1.40M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	40,000	$0.00	--
Exercise	Common Stock	40,000	$2.48	$99K
Sale	Common Stock	40,000	$35.1006	$1.40M

Holdings After Transaction: Stock Option (right to buy) — 136,268 shares (Direct); Common Stock — 65,000 shares (Direct)

Footnotes (1)

The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

Form 4 Insider Transactions: What Each Field Means →

03/27/2026 - 04:57 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Collins Helen Louise

(Last)

(First)

(Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER

COLORADO

80301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF MEDICAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/25/2026		M⁽¹⁾		40,000	A	$2.48	65,000⁽²⁾	D
Common Stock	03/25/2026		S⁽¹⁾		40,000	D	$35.1006⁽³⁾	25,000⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$2.48	03/25/2026		M⁽¹⁾			40,000	⁽⁵⁾	06/17/2031	Common Stock	40,000	$0	136,268	D

Explanation of Responses:

1. The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2025.

2. Certain of these securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

3. This transaction was executed in multiple trades at prices ranging from $35.00 to $35.25. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. These securities are RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

5. All of the shares subject to this option are fully vested and exercisable as of the date hereof.

	/s/ Ben Hohl, by power of attorney	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Enliven Therapeutics (ELVN) report for Helen Louise Collins?

Enliven Therapeutics reported that chief medical officer Helen Louise Collins exercised options for 40,000 shares at $2.48 per share and sold 40,000 common shares at a weighted average price of $35.1006, all on March 25, 2026.

Was the recent Enliven (ELVN) insider sale by Helen Collins pre-planned under a Rule 10b5-1 plan?

Yes. The filing states the option exercise and share sales by Helen Louise Collins were carried out under a Rule 10b5-1 trading plan adopted on October 19, 2025, indicating the transactions were pre-scheduled rather than timed at her discretion.

How many Enliven Therapeutics (ELVN) shares does Helen Collins hold after the Form 4 transactions?

After the reported transactions, Helen Louise Collins directly owns 25,000 shares of Enliven Therapeutics common stock and continues to hold 136,268 equity awards, including fully vested stock options and restricted stock units linked to the company’s common shares.

What type of equity awards does Helen Collins hold in Enliven Therapeutics (ELVN)?

The filing notes that Helen Louise Collins holds a mix of stock options and restricted stock units (RSUs). Certain reported securities are RSUs, with each RSU representing a contingent right to receive one share of Enliven Therapeutics common stock upon vesting conditions.